Market capitalization | $501.60m |
Enterprise Value | $367.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.34 |
P/S ratio (TTM) P/S ratio | 3.20 |
P/B ratio (TTM) P/B ratio | 1.83 |
Revenue growth (TTM) Revenue growth | 80.70% |
Revenue (TTM) Revenue | $156.72m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
13 Analysts have issued a REGENXBIO, Inc. forecast:
13 Analysts have issued a REGENXBIO, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 157 157 |
81%
81%
|
|
Gross Profit | 108 108 |
237%
237%
|
|
EBITDA | -141 -141 |
43%
43%
|
EBIT (Operating Income) EBIT | -157 -157 |
40%
40%
|
Net Profit | -158 -158 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Curran Simpson |
Employees | 353 |
Founded | 2008 |
Website | www.regenxbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.